ArticleBMC cancer2022

Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.

Federico Rojo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.